Effects of intravenous ABT-870 (iron (III)-hydroxide oligosaccharide) on mean arterial pressure and heart rate in the anaesthetized beagle: Comparison with other iron-containing haematinic agents

Clinical and Experimental Pharmacology and Physiology

Volumn 32, Issue 12, 2005, Pages 1020-1026

  Preusser, Lee C ^a   Fryer, Ryan M ^a   Gerhardt, Armin ^a   Hu, Yanhui ^a   Delgado Herrera, Leticia ^a   Melnick, Joel Z ^a   Williams, Laura A ^a   Cox, Bryan F ^a   Reinhart, Glenn A ^a  

^a ABBOTT LABORATORIES   (United States)

Author keywords

ABT 870; Blood pressure; Cardiovascular; End stage renal disease; Heart rate; Intravenous iron administration; Iron replacement therapy; Iron sucrose; Sodium ferric gluconate complex

Indexed keywords

ABT 870; ANTIANEMIC AGENT; DEXTRAN; FERRIC GLUCONATE; FERRIC HYDROXIDE SUCROSE; IRON (III) HYDROXIDE OLIGOSACCHARIDE; IRON DERIVATIVE; OLIGOSACCHARIDE; UNCLASSIFIED DRUG; ABT-870; ANTIHYPERTENSIVE AGENT; FERRIC ION;

ANESTHESIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD PRESSURE; CONTROLLED STUDY; DOG; DOSE RESPONSE; DRUG TOLERABILITY; HEART RATE; HYPOTENSION; HYPOTHESIS; IRON DEFICIENCY ANEMIA; IRON THERAPY; KIDNEY FAILURE; MALE; MEAN ARTERIAL PRESSURE; NONHUMAN; ANIMAL; CHEMISTRY; COMPARATIVE STUDY; DRUG EFFECT; INTRAVENOUS DRUG ADMINISTRATION;

ANIMALS; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; DEXTRANS; DOGS; FERRIC COMPOUNDS; HEART RATE; HEMATINICS; INFUSIONS, INTRAVENOUS; IRON COMPOUNDS; MALE; OLIGOSACCHARIDES;

EID: 33644972818     PISSN: 03051870     EISSN: 14401681     Source Type: Journal    
DOI: 10.1111/j.1440-1681.2005.tb00001.x     Document Type: Article

References (30)

1. US Renal Data System. USRDS 2004 Annual Data Report: Atlas of End-Stage Renal Disease in the United States. National Institues of Health, National Institutes of Diabetes and Digestive and Kidney Diseases, Bethesda, MD, 2004.
2. Eschbach J Haley N Adamson J. New insights into the treatment of the anemia of chronic renal failure with erythropoietin. Semin. Dial. 1990 3 : 112 21.
3. Van Wyck DB. Iron management during recombinant human erythropoietin therapy. Am. J. Kidney Dis. 1989 14 ( Suppl. 1 9 13.
4. Van Wyck DB Stivelman JC Ruiz J Kirlin LF Katz MA Ogden DA. Iron status in patients receiving erythropoietin for dialysis-associated anemia. Kidney Int. 1989 35 : 712 16.
5. Markowitz GS Kahn GA Feingold RE Coco M Lynn RI. An evaluation of the effectiveness of oral iron therapy in hemodialysis patients receiving recombinant human erythropoietin. Clin. Nephrol. 1997 48 : 34 40.
6. Taylor JE Peat N Porter C Morgan AG. Regular low-dose intravenous iron therapy improves response to erythropoietin in haemodialysis patients. Nephrol. Dial. Transplant. 1996 11 : 1079 83.
7. Fishbane S Frei GL Maesaka J. Reduction in recombinant human erythropoietin doses by the use of chronic intravenous iron supplementation. Am. J. Kidney Dis. 1995 26 : 41 6.
8. Macdougall IC Tucker B Thompson J Tomson CR Baker LR Raine AE. A randomized controlled study of iron supplementation in patients treated with erythropoietin. Kidney Int. 1996 50 : 1694 9.
9. Sunder-Plassmann G Horl WH. Importance of iron supply for erythropoietin therapy. Nephrol. Dial. Transplant. 1995 10 : 2070 6.
10. Sepandj F Jindal K West M Hirsch D. Economic appraisal of maintenance parenteral iron administration in treatment of anaemia in chronic haemodialysis patients. Nephrol. Dial. Transplant. 1996 11 : 319 22.
11. Senger JM Weiss RJ. Hematologic and erythropoietin responses to iron dextran in the hemodialysis environment. ANNA J. 1996 23 : 319 23.
12. Foundation NK. K/DOQI clinical practice guidelines for the treatment of anemia of chronic kidney disease, 2000. Am. J. Kidney Dis. 2001 37 ( Suppl. 1 S182 238.
13. Bailie GR Johnson CA Mason NA. Parenteral iron use in the management of anemia in end-stage renal disease patients. Am. J. Kidney Dis. 2000 35 : 1 12.
14. Edwards JH. Clinical review of the newer intravenous iron therapy options. Nephrol. Nurs. J. 2003 30 : 70 3.
15. Charytan C Levin N Al-Saloum M Hafeez T Gagnon S Van Wyck DB. Efficacy and safety of iron sucrose for iron deficiency in patients with dialysis-associated anemia: North American clinical trial. Am. J. Kidney Dis. 2001 37 : 300 7.
16. Nissenson AR Lindsay RM Swan S Seligman P Strobos J. Sodium ferric gluconate complex in sucrose is safe and effective in hemodialysis patients: North American Clinical Trial. Am. J. Kidney Dis. 1999 33 : 471 82.
17. Park L Uhthoff T Tierney M Nadler S. Effect of an intravenous iron dextran regimen on iron stores, hemoglobin, and erythropoietin requirements in hemodialysis patients. Am. J. Kidney Dis. 1998 31 : 835 40.
18. Nissenson AR Charytan C. Controversies in iron management. Kidney Int. Suppl. 2003 87 : S64 71.
19. Watson Pharmaceutical Inc. Ferrlecit (Sodium Ferric Gluconate Complex) Package Insert. Aventis Pharma, Dagenham. 2001.
20. American Reagent Laboratories Inc. Venofer (Iron Sucrose. Package Insert. American Reagent Laboratories, Shirley, NY. 2000.
21. Chandler G Elston O Davis C Macdougall I. Can higher doses of IV iron be given as a bolus injection. J. Am. Soc. Nephrol. 2000 11 ( Suppl. 260A.
22. Chandler G Harchowal J Macdougall IC. Intravenous iron sucrose: Establishing a safe dose. Am. J. Kidney Dis. 2001 38 : 988 91.
23. Taylor Pharmaceuticals. Promit. 150 mg/mL Injection Packet Insert. Taylor Pharmaceuticals, Decatur, IL. 1993.
24. Folkert VW Michael B Agarwal R et al. Chronic use of sodium ferric gluconate complex in hemodialysis patients: Safety of higher-dose (≥ 2 50 mg) administration. Am. J. Kidney Dis. 2003 41 : 651 7.
25. Folkert VW. Safety of high doses of non-dextran irons. Semin. Dial. 2003 16 : 285 6.
26. Kosch M Bahner U Bettger H Matzkies F Teschner M Schaefer RM. A randomized, controlled parallel-group trial on efficacy and safety of iron sucrose (Venofer) vs iron gluconate (Ferrlecit) in haemodialysis patients treated with rHuEpo. Nephrol. Dial. Transplant. 2001 16 : 1239 44.
27. Michael B Coyne DW Folkert VW Dahl NV Warnock DG. Sodium ferric gluconate complex in haemodialysis patients: A prospective evaluation of long-term safety. Nephrol. Dial. Transplant. 2004 19 : 1576 80.
28. ®) in haemodialysis patients. Nephrol. Dial. Transplant. 1996 11 : 820 4.
29. Sunder-Plassmann G Horl WH. Safety of intravenous injection of iron saccharate in haemodialysis patients. Nephrol. Dial. Transplant. 1996 11 : 1797 802.
30. Michael B Coyne DW Fishbane S et al. Sodium ferric gluconate complex in hemodialysis patients: Adverse reactions compared to placebo and iron dextran. Kidney Int. 2002 61 : 1830 9.